He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Subscribe To Our Newsletter & Stay Updated
